An in vivo study of breast carcinoma in a murine model treated with the HDAC inhibitor MS-275 demonstrated significantly reduced tumour growth, decreased VWF-positive blood vessels (decreased angiogenesis), decreased lung metastasis and reversed epithelial-mesenchymal transition (EMT) [92]. This evidence concerns the gene HDAC9 and neoplasm.